Overcoming resistance to checkpoint inhibitors in soft tissue sarcomas

2 Views

07/18/23

Zuzana Střížová, MD, PhD, Charles University, Prague, Czech Republic, discusses potential novel strategies for the management of soft tissue sarcomas. The tumor microenvironment makes immunotherapy unsuitable for treating patients and in an analysis of patients, macrophages were the dominant type of immune cells present. However, combining immune checkpoint inhibitors such as nivolumab and an anti-CD47 antibody has not proven to be efficacious in improving survival. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.